Under a tenth of individuals who could benefit from obesity jabs like Wegovy can access them, caution the global health agency as it releases its initial recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now obese, it is calling for broader and more equitable access to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The new guidelines affirms that obesity is a lifelong illness that can be treated with thorough and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key barriers to broad access to the injections that can aid individuals in losing considerable body mass, notes the agency.
Skinny Jab Shortage
Despite the current most favorable case, the manufacturing of such drugs could only cover around 100 million people – fewer than 10% of the global need, according to the WHO.
The guideline encourages nations and manufacturers to widen access, through strategies like licensing agreements.
Exclusive production rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of countries in 2026.
How Weight-Loss Drugs Function
These medications imitate a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so users eat less.
People usually begin shedding pounds after several weeks of beginning the regular doses.
Evidence indicates users may put most of the weight back on after a year of discontinuing the treatment, as their normal food cravings come back.
To be carrying excess weight elevates your risk for developing health problems, including type 2 diabetes, heart disease, brain attack, and certain malignancies.
Obesity affects people in all nations and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.
